OPNT
Opiant Pharmaceuticals, Inc.
Set alert
20.65 0.00 0.00%
20.56 Day range 20.94
52-week range unavailable
- Open
- 20.88
- Prev close
- 20.65
- Mkt cap
- 108.80M
- Vol
- 562.78K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 20.56
- High
- 20.94
- Forward P/E
- -4.88
- Beta
- 0.83
- Short ratio
- 0.56
- Inst. own
- 42.00%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 21, 2023
- 50-d avg
- 20.50
- 200-d avg
- 14.79
- 1y target
- 21.00
Key statistics
- Market cap
- 108.80M
- Enterprise value
- 87.85M
- Trailing P/E
- 0.00
- Forward P/E
- -4.88
- PEG ratio
- 0.00
- Price / sales
- 4.87
- Price / book
- 5.20
- EPS (TTM)
- -6.53
- Beta
- 0.83
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -148.13%
- Revenue (TTM)
- 22.34M
- Revenue growth
- -98.90%
- Free cash flow
- -2.86M
- Total cash
- 35.38M
- Total debt
- 16.51M
- Return on equity
- -105.87%
- Shares outstanding
- 5.27M
- Short % of float
- 0.84%
- 50-day average
- 20.50
- 200-day average
- 14.79
Analyst view
Consensus: hold
Hold
Price target (mean) 21.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 21, 2023
Expected Mar 21, 2023. Consensus EPS estimate -1.21.
Financials — quick view
OPNT Revenue — quarterly 173.87K
OPNT Net income — quarterly -9.92M
OPNT EPS — quarterly -1.93
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 21, 2023 | Dec 1, 2022 | -2.46 | — | — | — |
| Nov 14, 2022 | Sep 1, 2022 | -1.51 | — | — | — |
| Aug 11, 2022 | Jun 1, 2022 | -1.29 | — | — | — |
| May 10, 2022 | Mar 1, 2022 | -0.75 | — | — | — |
| Mar 15, 2022 | Dec 1, 2021 | 0.10 | — | — | — |
| Nov 11, 2021 | Sep 1, 2021 | 0.15 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 9, 2021 | Oppenheimer | init | — | Outperform |
| Sep 28, 2018 | Cantor Fitzgerald | main | Overweight | Overweight |
| Jun 12, 2018 | Cantor Fitzgerald | init | — | Overweight |
| Nov 30, 2012 | Mizuho | down | Buy | Neutral |
| May 5, 2018 | B. Riley FBR | down | Buy | Neutral |
| Oct 31, 2012 | Evercore Partners | down | Overweight | Equal-Weight |
About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- opiant.com
News
- What's The Opiant CVR Worth?
- Opiant Pharmaceuticals: Nano-Cap Buyout With Interesting CVR Thrown In
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ELVT, OPNT, BNFT, ABMD
- Why Is Opiant Pharma (OPNT) Stock Up 116% Today?
- Earnings Scheduled For November 14, 2022
- Opiant Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 14, 2022
- Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q2 2022 Results - Earnings Call Transcript
- Earnings Scheduled For August 11, 2022
- Opiant Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022
- Opiant Pharmaceuticals, Inc. (OPNT) CEO Dr. Roger Crystal on Q1 2022 Results - Earnings Call Transcript
Your note
Sign in to keep a note on OPNT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| COLLARD CRAIG A | Director | Stock Award(Grant) | Jun 13, 2022 | 55,822 |
| CRYSTAL ROGER | Chief Executive Officer | Sale | Jan 26, 2023 | 75,339 |
| DALY RICHARD J | Director | Stock Award(Grant) | Jun 13, 2022 | 7,800 |
| ELLISON MARK JASON HEATH | Officer | Sale | Jan 26, 2023 | 18,751 |
| GORMAN BRIAN | General Counsel | Sale | Jan 26, 2023 | 31,990 |
| O'TOOLE DAVID D | Chief Financial Officer | Sale | Jan 26, 2023 | 34,248 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Western Standard, LLC | 15.02% | 424,080 | 8.76M | Dec 30, 2022 |
| Apis Capital Advisors, LLC | 7.58% | 214,000 | 4.42M | Dec 30, 2022 |
| Morgan Stanley | 7.00% | 197,652 | 4.08M | Dec 30, 2022 |
| Vanguard Group, Inc. (The) | 6.76% | 190,773 | 3.94M | Dec 30, 2022 |
| Renaissance Technologies, LLC | 5.19% | 146,415 | 3.02M | Dec 30, 2022 |
| Wells Fargo & Company | 4.85% | 136,814 | 2.83M | Dec 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 4.26% | 120,263 | 2.48M | Sep 29, 2022 |
| Vanguard Extended Market Index Fund | 2.21% | 62,250 | 1.29M | Sep 29, 2022 |
| IndexIQ Tr-IQ Merger Arbitrage ETF | 2.19% | 61,912 | 1.28M | Dec 30, 2022 |
| DFA U.S. Targeted Value Portfolio | 1.05% | 29,507 | 609.32K | Oct 30, 2022 |
| Fidelity Extended Market Index Fund | 0.99% | 27,806 | 574.19K | Nov 29, 2022 |
| DFA U.S. Small Cap Series | 0.65% | 18,273 | 377.34K | Oct 30, 2022 |